<DOC>
	<DOCNO>NCT02172378</DOCNO>
	<brief_summary>Determine effect 12-week treatment inhale tiotropium bromide lung function static lung volume , correlate effect dyspnoea COPD patient .</brief_summary>
	<brief_title>12-week Treatment With Inhaled Tiotropium ( 18 mcg Once Daily ) Lung Function Static Lung Volumes Stable , Moderate Severe Chronic Obstructive Pulmonary Disease ( COPD ) Patients . Correlation Dyspnoea Scales</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Dyspnea</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>1 . Male female patient 40 year age old . 2 . All patient diagnosis COPD meet follow spirometric static lung volume criterion : 1 . Patients relatively stable , moderate severe airway obstruction : FEV1 ≤ 50 % predict value , FEV1/SVC ≤ 70 % . 2 . All patient presence lung hyperinflation demonstrate RV ≥ 125 % predict value . Predicted normal value calculate accord European Community Coal Steel ( ECCS ) Males : FEV1 predict ( L ) = 4.30 x height ( metre ) 0.029 x age ( year ) 2.49 RV predict ( L ) = 1.31 x height ( metre ) + 0.022 x age ( year ) 1.23 Females : FEV1 predict ( L ) = 3.95 x height ( metre ) 0.025 x age ( year ) 2.60 RV predict ( L ) = 1.81 x height ( metre ) 0.016 x age ( year ) 2.00 3 . Patients current exsmokers smoke history 10 packyears ( p.y. ) . Patients never smoke cigarette exclude . Number p.y . = Number cigarettes/day / 20 x year smoke 4 . Patients able perform study related test include SWT , acceptable pulmonary function test include PEFR measurement , able maintain record study period require protocol . 5 . Patients able inhale medication HandiHaler . 6 . All patient sign inform consent form prior participation trial i.e . prior prestudy washout usual pulmonary medication . 7 . Eosinophilia &lt; 600/mm³ document past year ( available , blood count cell perform ) . 1 . Patients history asthma , allergic rhinitis atopy . 2 . Patients significant disease COPD exclude . A significant disease define disease opinion investigator may either put patient risk participation study disease may influence result study patient 's ability participate study . 3 . Patients recent history ( i.e . one year less ) myocardial infarction . 4 . Patients recent history ( i.e . three year less ) heart failure , pulmonary oedema , patient cardiac arrhythmia require drug therapy . 5 . Patients regularly use daytime oxygen therapy one hour per day investigator.s opinion unable abstain use oxygen therapy . 6 . Patients know active tuberculosis . 7 . Patients history cancer within last five year . Patients treat basal cell carcinoma allow . 8 . Patients history lifethreatening pulmonary obstruction , history cystic fibrosis bronchiectasis . 9 . Patients underwent thoracotomy pulmonary resection . Patients history thoracotomy reason evaluate per exclusion criterion No . 2 . 10 . Patients low respiratory tract infection past six week prior Screening Visit ( Visit 1 ) runin period . 11 . Patients currently pulmonary rehabilitation programme complete pulmonary rehabilitation programme six week prior Screening Visit ( Visit 1 ) . 12 . Patients know hypersensitivity anticholinergic drug , lactose component inhalation capsule delivery system . 13 . Patients know symptomatic prostatic hypertrophy bladder neck obstruction . 14 . Patients know narrowangle glaucoma . 15 . Patients treat βblockers , cromolyn sodium nedocromil . 16 . Patients treated antihistamine ( H1 receptor antagonist ) antileukotrienes . 17 . Patients treat monoamine oxidase inhibitor tricyclic antidepressant . 18 . Patients use oral corticosteroid medication unstable dos ( i.e . le six week stable dose ) dose excess equivalent 10 mg prednisone per day 20 mg every day . 19 . Pregnant nursing woman woman childbearing potential use medically approve mean contraception ( i.e . oral contraceptive , intrauterine device , diaphragm subdermal implant ) . 20 . Patients history and/or active significant alcohol drug abuse . 21 . Patients take another investigational drug within one month ten half life ( whichever great ) prior Visit 1 .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>